(Q38433654)

3 September 2017

0 references

Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials (English)

1 reference

3 September 2017

0 references

Jue Jiang

1

1 reference

PubMed ID

25899425

3 September 2017

Hong Jiang

series ordinal

2

1 reference

3 September 2017

22 April 2015

1 reference

3 September 2017

Neurological Sciences

1 reference

3 September 2017

36

1 reference

3 September 2017

9

1 reference

3 September 2017

1633-1641

1 reference

https://scigraph.springernature.com/pub.10.1007/s10072-015-2221-2

3 September 2017

0 references

cites work

Worldwide prevalence and incidence of dementia

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Meta-analysis of six-month memantine trials in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Intention-to-treat analysis: implications for quantitative and qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2221-2

Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial

21 January 2018

1 reference

12 December 2020

Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.

1 reference

12 December 2020

Effectiveness and safety of memantine treatment for Alzheimer's disease

1 reference

12 December 2020

Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial.

1 reference

12 December 2020

10.1007/S10072-015-2221-2

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

25899425